NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Veru Inc. VERU
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Dividend streak
1 yrs
Raised every year since 2025
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-89.7%
Net margin · FY25
—
Dividend coverage
0.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
—
Diluted EPS, FY2025
EPS
Dividend
Earnings covered only a fraction of the dividend — the rest came from cash or borrowing.
Profitability
-89.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-50.4%
Each USD of equity lost 90 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises1 years
Growth
−11.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−34.9%
−11.9%
−3.6%
−3.2%
Dividend / share
+1.6%
Returned to shareholders
−90.1%
−72.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+66.0%
Change, 10 years—
The share count grew 66% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 29.8M
total assets, end of FY2025
Total assetsUSD 29.8M
EquityUSD 18.3M
CashUSD 15.8M
Current ratio2.43×
Equity funds 61% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.1
0.0
−0.0
·
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
·
·
−1.10
−1.05
0.09
−0.28
−0.19
−0.44
−0.25
0.01
0.15
0.08
0.50
0.53
0.19
0.24
0.24
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
0.21
0.07
0.22
0.20
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
0
250
52
40
103
61
·
ROE %
−89.7
−145.4
−181.8
−70.8
8.0
−60.8
−38.9
−61.4
−16.1
1.0
14.2
8.2
51.6
74.7
32.8
46.3
50.4
Shares out B
0.01
0.01
0.09
0.08
0.08
0.07
0.07
0.06
0.05
0.03
0.03
0.03
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed